New York-based Pfizer desperately needs a large acquisition and the resulting synergies to reinvigorate its tepid earnings growth rate, also Allergan would help New York-based Pfizer escape the uncompetitive U.S. corporate tax rate, which has led company after company to domicile away from its shores.